Gene Expression in Tissue From Patients With Acute Lymphoblastic Leukemia

Launched by ECOG-ACRIN CANCER RESEARCH GROUP · May 9, 2009

Keywords

ClinConnect Summary

OBJECTIVES:

* Identify genes involved in specific biologic processes or molecular functions that contribute to the mechanisms by which the BCR/ABL tyrosine kinase induces a leukemic phenotype using RNA banked from patients with BCR/ABL-positive acute lymphoblastic leukemia (ALL) enrolled on ECOG-2993.
* Compare patterns of mRNA expression of BCR/ABL fusion protein in patients with B-lineage ALL vs patients with ALL and no cytogenetic abnormalities enrolled on ECOG-2993.
* Determine both shared and differing expression patterns in patients with BCR/ABL-positive and cytogenetically negative ...

Gender

ALL

Eligibility criteria

• DISEASE CHARACTERISTICS:
• • Confirmed diagnosis of acute lymphoblastic leukemia
• * Tissue banked on protocol ECOG-2993 meeting the following criteria:
• • Leukemic blast cell population immunophenotyped in detail (e.g., including CD25) in ECOG's Immunophenotyping Reference Laboratory
• • Flow cytometric analysis of gated blast cells reveals association with the B-cell lineage
• • Mononuclear cell fraction used for RNA isolation contains 75-99% blasts (median 85%)
• • Negative for TEL/AML1, MLL/AF4, and E2A/PBX1 by qualitative reverse transcription-polymerase chain reaction (RT-PCR)
• • No FLT3 gene mutations
• * BCR/ABL-positive samples meeting the following criteria:
• • Presence of t(9;22)(q34;q11) by standard cytogenetics
• • Detection of either p190 BCR/ABL or p210 BCR/ABL transcripts by qualitative RT-PCR
• * Patients with genetic risk factors must meet the following criterion:
• • Only a normal diploid karyotype is present in ≥ 15 metaphases by standard cytogenetics
• PATIENT CHARACTERISTICS:
• • Not specified
• PRIOR CONCURRENT THERAPY:
• • Not specified